Mamy ANDRIANTERANAGNA

Dr. Mamy ANDRIANTERANAGNA

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2019 in New Phytologist
Verified
Journal Article
Closed access
PDF file
MNManuel Nieves-Cordones
Manuel Nieves-Cordones
MAMamy ANDRIANTERANAGNA
Mamy ANDRIANTERANAGNA
TCTeresa Cuellar
Teresa Cuellar
ICIsabelle Chérel
Isabelle Chérel
RGRémy Gibrat
Rémy Gibrat
IGIsabelle Gaillard
Isabelle Gaillard

2 August 2024 in American Journal of Surgical Pathology
Verified
Journal Article
Open access
JCJoanna Cyrta
Joanna Cyrta
RBRiwan Msc Brillet
Riwan Msc Brillet
ELEnora Laas
Enora Laas
PJPierre-Alexandre Just
Pierre-Alexandre Just
MAMamy ANDRIANTERANAGNA
Mamy ANDRIANTERANAGNA
JMJulien Masliah-Planchon
Julien Masliah-Planchon

5 August 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MMMatthieu Meryet-Figuière
Matthieu Meryet-Figuière
MVMegane Vernon
Megane Vernon
MAMamy ANDRIANTERANAGNA
Mamy ANDRIANTERANAGNA
BLBernard Lambert
Bernard Lambert
CBCélia Brochen
Célia Brochen
CDChristophe Denoyelle
Christophe Denoyelle
The identification of miRNAs’ targets and associated regulatory networks might allow the definition of new strategies using drugs whose association mimics a given miRNA’s effects. Based on this assumption we devised a multi-omics approach to precisely characterize miRNAs’ effects. We combined miR-491-5p target affinity purification, RNA microarray, and mass spectrometry to perform an integrated analysis in ovarian cancer cell lines. We thus constructed an interaction network that highlighted highly connected hubs being either direct or indirect targets of miR-491-5p effects: the already known EGFR and BCL2L1 but also EP300, CTNNB1 and several small-GTPases. By using different combinations of specific inhibitors of these hubs, we could greatly enhance their respective cytotoxicity and mimic the miR-491-5p-induced phenotype. Our methodology thus constitutes an interesting strategy to comprehensively study the effects of a given miRNA. Moreover, we identified targets for which pharmacological inhibitors are already available for a clinical use or in clinical trials. This study might thus enable innovative therapeutic options for ovarian cancer, which remains the leading cause of death from gynecological malignancies in developed countries.

24 August 2026
Verified
Dataset
Closed access
CHCaroline Hoffmann
Caroline Hoffmann
JWJan-Timon Werle
Jan-Timon Werle
PSPhilémon Sirven
Philémon Sirven
JGJocelyn Gal
Jocelyn Gal
MAMamy ANDRIANTERANAGNA
Mamy ANDRIANTERANAGNA
HSHélène Salmon
Hélène Salmon
BioStudies – one package for all the data supporting a study


15 October 2026
Verified
Other
Open access
CCCéline Chauvin
Céline Chauvin
RWRyszard Wimmer
Ryszard Wimmer
LBLudovica Brunetti
Ludovica Brunetti
JCJoanna Cyrta
Joanna Cyrta
ABAna Boranijasevic
Ana Boranijasevic
FBFranck Bourdeaut
Franck Bourdeaut
Table S1 from DNMT3B Plays Antagonistic Roles with SMARCB1 and Is a Targetable Vulnerability in Rhabdoid Tumors